Voluntary nationwide recall: Cyclobenzaprine (Unichem – August 2025)

Sep. 2025Pharmacy Updates

Unichem Pharmaceuticals (USA), Inc. is recalling one lot, lot GMML24026A, of Cyclobenzaprine Hydrochloride Tablets USP 10 mg. Cyclobenzaprine is used for the relief of muscle spasms from certain conditions.

This drug is being recalled because a Cyclobenzaprine 10 mg (90-count) label was accidentally placed on a bottle containing Meloxicam 7.5 mg tablets. Meloxicam is a nonsteroidal anti-inflammatory drug and is used for the treatment of certain types of arthritis. Meloxicam Tablets, USP, 7.5 mg are light yellow, round, flat, beveled-edged tablets with “U & L” debossed on one side and “7.5” debossed on the other side. Using Meloxicam unknowingly if it is not prescribed for you may cause any of several different serious adverse events—particularly in people taking other nonsteroidal anti-inflammatory drugs or blood thinners, people who have allergies to Meloxicam, or people with underlying illness.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Cyclobenzaprine, you should stop using the product and return it to the place of purchase. If you have experienced any problems that may be related to taking this product, you should contact your doctor or health care provider.

As of Aug. 27, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Inmar at 1-877-840-5109. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. CST.
  • Visit the FDA website.

Recent Announcements

Asymptomatic Severe Coronary Disease: Detection to Decisions. Do We Know The Proper Management?

In this new CME course, Krishna V. Tummalapalli, MD, interventional cardiologist, UPMC Heart and Vascular Institute, discusses how to explain the importance of early detection of coronary artery disease, as well as how to describe how early identification can reduce future cardiovascular events and identify appropriate first line medical therapy strategies for patients with asymptomatic stable ischemic heart disease.
Mar. 2026Education/Webinars

2026 Preventive Care Rewards Program

Preventive Care Rewards Program
Mar. 2026Important Notices

CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care

Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.
Feb. 2026Education/Webinars